Interim analysis demonstrates best-in-class clinical remission in 55.3% of 217 ulcerative colitis (UC) patients (full analysis set) after 48 weeks of once-daily oral 50mg ABX464

Moreover, in the subgroup of patients who had at least a clinical response after the 8-week induction study (n=121), 65.3% achieved clinical remission during the first year of maintenance treatment (full analysis set)

Endoscopic improvement and endoscopic remission at week 48 achieved by 61.8% and 33.6% of the patients respectively (full analysis set)

Good safety and tolerability profile supports chronic use of ABX464 Final preparations to launch ABX464 global pivotal phase 3 clinical program in UC ongoing, inclusion of first patients is expected in Q3 2022